摘要
目的探讨为高龄肺心病心力衰竭患者应用米力农治疗的实际效果,分析其临床应用价值。方法选取2013年9月-2014年3月我院收治的高龄肺心病心力衰竭患者40例,随机将其分成实验组20例,对照组20例,给予对照组螺内酯、美托洛尔、卡托普利等药物进行常规治疗,实验组在此基础上应用米力农治疗,观察临床疗效及用药安全性。结果两组病例均未发生恶性不良反应,实验组药物治疗有效率为90.0%,高于对照组的65.0%(P<0.05)。结论米力农治疗高龄肺心病心力衰竭,疗效显著,安全性高,可在肺心病并心力衰竭患者中推广。
Objective To investigate the clinical efficacy and value of milrinone in the treatment of pulmonary heart disease associated with heart failure in the elderly. Methods Forty elderly patients with pulmonary heart disease associated with heart failure who were admitted to our hospital from September 2013 to September 2014 were randomly and equally divided into treatment group and control group. The control group was given conventional therapy including spironolactone, metoprolol, and captopril. The treatment group was given rnilrinone in addition to conventional therapy. The clinical outcome and safety were evaluated. Results There were no adverse reactions in either group. The treatment group had a significantly higher response rate than the control group （90.0% vs 65.0%, P〈0.05）. Conclusion Milrinone is effective and safe in the treatment of pulmonary heart disease associated with heart failure in the elderly, which holds promise for widespread application.
出处
《心血管病防治知识（学术版）》
2015年第1期72-74,共3页
Prevention and Treatment of Cardiovascular Disease
关键词
米力农
高龄
肺心病
心力衰竭
安全性
Milrinone
Elderly
Pulmonary heart disease
Heart failure
Safety
